CRBUCaribou Biosciences, Inc.

$186M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-3.1% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$43M-1823.8% margin

Net Income

-$40M-1699.6% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+13.3%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$38M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$274M

Total Liabilities

$56M

Stockholders' Equity

$217M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-3.1%
Gross Profit	$2M	$2M	+36.9%
Operating Income	-$43M	-$46M	+6.7%
Net Income	-$40M	-$41M	+3.0%

Revenue Segments

Reportable Segment

$2M100%

Geographic Segments

UNITED STATES

$2M95%

Non-US

$129,0005%

CRBU Q1 2025 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena